Literature DB >> 31245417

One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade.

Aditi Gupta1, Sadna Budhu1, Taha Merghoub1.   

Abstract

Year:  2019        PMID： 31245417      PMCID： PMC6561888          DOI： 10.21037/hbsn.2019.01.10

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  14 in total

Review 1.  Antigen specificity of immune suppression by myeloid-derived suppressor cells.

Authors:  Samantha Solito; Vincenzo Bronte; Susanna Mandruzzato
Journal:  J Leukoc Biol       Date:  2011-04-12       Impact factor: 4.962

2.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.

Authors:  Claire Vanpouille-Box; Julie M Diamond; Karsten A Pilones; Jiri Zavadil; James S Babb; Silvia C Formenti; Mary Helen Barcellos-Hoff; Sandra Demaria
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

Review 3.  Targeting the TGFβ pathway for cancer therapy.

Authors:  Cindy Neuzillet; Annemilaï Tijeras-Raballand; Romain Cohen; Jérôme Cros; Sandrine Faivre; Eric Raymond; Armand de Gramont
Journal:  Pharmacol Ther       Date:  2014-11-06       Impact factor: 12.310

Review 4.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

5.  Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Authors:  David J Messenheimer; Shawn M Jensen; Michael E Afentoulis; Keith W Wegmann; Zipei Feng; David J Friedman; Michael J Gough; Walter J Urba; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2017-08-28       Impact factor: 12.531

Review 6.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

7.  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.

Authors:  Yan Lan; Dong Zhang; Chunxiao Xu; Kenneth W Hance; Bo Marelli; Jin Qi; Huakui Yu; Guozhong Qin; Aroop Sircar; Vivian M Hernández; Molly H Jenkins; Rachel E Fontana; Amit Deshpande; George Locke; Helen Sabzevari; Laszlo Radvanyi; Kin-Ming Lo
Journal:  Sci Transl Med       Date:  2018-01-17       Impact factor: 17.956

Review 8.  TGF-β activation and function in immunity.

Authors:  Mark A Travis; Dean Sheppard
Journal:  Annu Rev Immunol       Date:  2013-12-02       Impact factor: 28.527

Review 9.  Novel TGF-β inhibitors ready for prime time in onco-immunology.

Authors:  Armand de Gramont; Sandrine Faivre; Eric Raymond
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962
View more
  4 in total

1.  Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids.

Authors:  Lejia Sun; Huayu Yang; Yilei Mao
Journal:  Ann Transl Med       Date:  2019-12

Review 2.  Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.

Authors:  Xiaohui Wang; Zhiqiang Wu; Wei Qiu; Ping Chen; Xiang Xu; Weidong Han
Journal:  Front Med       Date:  2020-08-13       Impact factor: 4.592

3.  Laminin γ2-mediating T cell exclusion attenuates response to anti-PD-1 therapy.

Authors:  Lei Li; Jia-Ru Wei; Jun Dong; Qing-Guang Lin; Hong Tang; Yong-Xu Jia; Wanlin Tan; Qing-Yun Chen; Ting-Ting Zeng; Shan Xing; Yan-Ru Qin; Ying-Hui Zhu; Yan Li; Xin-Yuan Guan
Journal:  Sci Adv       Date:  2021-02-03       Impact factor: 14.136

4.  Modular assembly-based approach of loosely packing co-cultured hepatic tissue elements with endothelialization for liver tissue engineering.

Authors:  Jianyu He; Yuan Pang; Huayu Yang; Kevin Montagne; Marie Shinohara; Yilei Mao; Wei Sun; Yasuyuki Sakai
Journal:  Ann Transl Med       Date:  2020-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.